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ABSTRACT 
Multiple Sclerosis (MS) is an incurable autoimmune disorder that attacks the myelin 
sheath surrounding nerve cells. Steady demyelination of these cells over time results in 
painful inflammation and reduced mobility. Genetic abnormalities could be responsible 
for the onset of this disease. Chromosomal mutations found in MS patients as well as 
environmental factors influencing the expression of certain genes will be analyzed in this 
review. Moreover, treatments regulating gene expression in MS patients will be 
discussed. Further genetic research would not only provide scientists and medical 
professionals with a deeper understanding of MS and other autoimmune disorders, but 
also lead to the development of more effective treatments. Recent findings have 
enabled scientists to identify genes in MS patients that are absent in healthy patients, 
but researchers struggle to find a common thread tying these genes together. This is just 
one of the many reasons why MS is still considered an idiopathic disease. 
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INTRODUCTION 
Multiple sclerosis is a neurological autoimmune disorder that degrades an individual’s 
quality of life. The body’s immune cells attack each neuron’s myelin sheath, causing 
chronic inflammation and degradation of myelin tissue.1 Electrical signals sent from the 
brain cannot travel at high enough speeds without this myelin coating.1 These 
unfavorable immune responses are a result of malfunctioning immune cells. Killer T-cells 
and B-cells misidentify the body’s own tissues as foreign, provoking an unnecessary 
response.2 Over time, this nerve damage can be so intense it could cause other unrelated 
health issues to develop.2 
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Due to the depth and complexity of the immune system, there is no known cause or cure 
for multiple sclerosis. MS can present in a variety of ways, making it difficult to diagnose. 
Common symptoms include limb weakness, vision impairment, and depression; 
however, patients have identified ailments like urinary tract infections and trouble 
swallowing as symptoms as well.3 Another prevalent symptom is Lhermitte’s sign, which 
causes intense pain in the spinal column.4 Though frequently seen in MS diagnoses, this 
symptom can also appear in individuals that suffered spinal cord trauma or have depleted 
vitamin B12 levels.4  Furthermore, uncommon symptoms do not indicate a better 
prognosis for the afflicted.5 Incidences of relapse between individuals presenting either 
common or uncommon symptoms are almost identical.5 A viable way to make sense out 
of these symptoms is through genetic research. Tying these symptoms to chromosomal 
loci can make MS easier to identify and treat. Evidence now suggests that a combination 
of genetics and the environment influences the onset of the disease. This allows 
researchers to narrow their scope and assess how geographical, cultural, or 
socioeconomic surroundings could influence gene expression in MS patients. Though 
recent evidence is promising, this research framework still possesses several limitations, 
including the ability to directly link these genetic abnormalities to one another.  This 
review will focus on gene interaction and expression, as well as environmental factors 
that influence their expression. Moreover, drug therapies affecting gene regulation will 
also be explored.  
 
GENETIC FINDINGS 
Mutations 
Mutations in certain genes are not only common to MS patients, but also result in 
abnormal T-cell production. For example, mutations in the FoxP3 gene lead to the 
production of malformed regulatory T-cells, causing immune responses to go 
unmonitored.6 Consequently, the body cannot stop attacks on its own tissues.6 
Moreover, with the sequencing of the human genome, scientists have identified NR1H3 
as a problem in MS patients, especially in those with a family history of the disease.7 
NR1H3 codes for receptors that regulate fatty acid formation and function as well as 
inflammatory response.8 A mutation in this gene creates pathogenic variants that inhibit 
production of the receptor in highly metabolic tissues, including ones in the brain.7 
Deregulation of these receptors can cause inflammatory episodes like the ones seen in 
multiple sclerosis patients.  
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Gene Expression 
Patients that develop multiple sclerosis exhibit a vast range of symptoms, but current 
research data cannot unanimously determine just one genetic abnormality that triggers 
MS. However, recent developments support a hypothesis that alternative gene 
expression could play a role in onset of the disease. Comparison of blood assays between 
healthy and afflicted individuals showed 99 alternatively spliced RNA sequences, with 19 
of them bearing statistical significance.9 Most of the pathologically spliced genes were 
responsible for inflammatory and developmental disorders, especially in skeletal and 
muscular tissues.9 These instances of alternative gene expression would drive 
inflammation in the myelin tissue of multiple sclerosis patients.   
 
To make matters even more complicated, gene expression patterns are inconsistent and 
can vary based on the tissue. A recent study showed that based on the type of MS 
diagnosis and its duration in the patient, tissues in the brain can be at different stages of 
myelination.10 The same study also observed expression patterns of twelve genes seen 
in brain lesions caused by demyelination disorders.10 Among the four tissue types tested 
from patients at different stages of MS diagnosis, only half of the observed genes (NKX2-
2, SOX10, SEMA3B, CXCL12, STAT6, MOG) showed an increase or decrease in 
expression rate, while the other half (IGF1, IGF2, IL4, IL4R, MAL, PLP1) showed no trend 
in expression rate.10 The irregularity in expression rate across these tissue types makes it 
near impossible to determine which genes have the greatest effect at varying stages of 
MS. Even in the genes that do exhibit a trend, it is still unclear how these genes are 
regulated and how they might affect one another. 
 
ENVIRONMENTAL INFLUENCES 
Twin studies are one of the most reliable ways to test genetics against environment. 
Research suggests that external influences, especially during embryonic and childhood 
development, has a greater influence on the expression of MS than the genetics 
themselves. According to a meta-analysis conducted on multiple twin studies, the shared 
environment and similar upbringing experienced by twins (either monozygotic or 
dizygotic) causes MS to manifest similarly in both individuals 10% to 30% of the time.11 
This correlation establishes a link between quality and type of living and MS diagnosis.  
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Moreover, geographic location can trigger MS in those with a family history of the 
disease.12 This phenomenon could have to do with the way circadian rhythm genes are 
expressed in individuals who live in these extreme northern or southern regions of the 
Earth. Two genotypic variants on both ARNTL and CLOCK, which regulate circadian 
rhythm, display a statistically significant correlation with MS diagnosis.12 Another 
experiment hypothesized that ZMIZ1, a gene poorly expressed in MS patients, was 
influenced by vitamin D levels, which are affected by accessibility to sunlight.13 In this 
study, blood samples of MS patients and healthy controls were collected separately in 
the summer and winter months to see how ZMIZ1 expression was affected by the time 
of year.13 ZMIZ1 expression was the same in MS patients for both the summer and winter 
months, but expression increased in the winter for the healthy controls.13 Therefore, the 
results of this study concluded that while ZMIZ1 expression is an issue in MS patients, 
vitamin D and sunlight availability are not factors influencing the expression of that gene.  
 
The genes discussed here are not directly related and do not have the same effects on 
the body, indicating the need for more investigation into the theory of geography and 
sunlight. Other factors, such as diet, exercise, and lifestyle could also be altering gene 
expression, but there is currently not enough research to support any one of these 
factors.  
 
TREATMENTS 
Although scientists have yet to find a cure for multiple sclerosis, a number of drug 
therapies are being explored to regulate gene expression in MS patients. Most of these 
experimental drugs are administered to mice with an induced form of MS known as 
experimental autoimmune encephalomyelitis (EAE).6, 14 Atorvastatin is one of these 
drugs, which involves the FoxP3 and STAT6 genes discussed in a previous section.15 In 
mice with low STAT6 expression, a 1 mg/kg dose of atorvastatin prevented EAE from 
maturing and reversed inflammatory damage in mice with more advanced stages of 
EAE.15 Conversely, a 10 mg/kg dose of atorvastatin did not increase presence of 
regulatory T-cells created by FoxP3, suggesting that gene expression was not enhanced 
by this drug.15 Further genetic research might lead to the development of a drug that 
increases FoxP3 expression and the production of healthy T-cells.  
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Additionally, these treatment studies have allowed scientists to focus on specific 
proteins, such as the myelin binding protein (MBP). Pathogenic conformations of this 
protein trigger immune responses, while the appropriate conformations shut these 
responses down. Evidence suggests that when administered, MBP87-99 turns off 
production of MBP72-85, the harmful protein that can cause an inflammatory episode 
(Table 1).14 Furthermore, researchers have adopted genetic engineering techniques to 
help fix MBP expression levels. XBD173 is an artificial protein ligand developed to treat 
experimental autoimmune encephalomyelitis by targeting MBP.16 Three separate 
groups were administered XBD173 in doses of either 10 mg/kg, 20 mg/kg, or 30 mg/kg.16 
Although scientists anticipated the highest dose to have the greatest impact, the results 
concluded that the lowest dose was the most effective at lessening symptom intensity 
and restoring MBP expression levels.16 Smaller doses of the ligand taken over an 
extended period of time presented less side effects and had a more therapeutic outcome 
than larger doses (Table 1).16  There are a variety of ways to approach MS treatment with 
genetics, and studies like this show a promising future for development of treatments 
influencing genetic makeup.   
 
Table 1. Comparison of Treatment Methods Involving Myelin Basic Protein (MBP) in 
Mice with Experimental Autoimmune Encephalomyelitis (EAE).  
 
 
CONCLUSION 
The research conducted on multiple sclerosis impacts studies on all autoimmune 
diseases, especially when it comes to their genetic components. Being able to isolate loci 
on chromosomes allows us to identify new biomarkers that code for pathogenic 
characteristics. While there is no known cause or cure for multiple sclerosis, genetic 
research has allowed scientists to narrow their focus to target individual genes, proteins, 
and metabolic pathways. In many cases, genetics alone aren’t to blame, as certain 
environmental stressors increase the odds of the disease being expressed. Although 
there are still significant gaps in MS research, new drug therapies are constantly being 
 8 
 
developed to help patients cope with debilitating symptoms. Continued research in the 
field of genetics would improve accuracy of diagnosis, explain why MS can present in so 
many ways, and lead to the development of drugs that could regulate expression of 
specific genes. If all gene loci associated with multiple sclerosis are identified, genetic 
screening could be used to determine pre-disposition to the disease and assess risk 
factors. This has the potential to improve prognosis and give diseased individuals the 
opportunity to lead a normal life.  
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